Genfit targets long-term royalties as IQVIA projects U.S. NIS-based MASH test sales topping USD 1.5 billion by 2033

PUBT · 2d ago
Genfit targets long-term royalties as IQVIA projects U.S. NIS-based MASH test sales topping USD 1.5 billion by 2033
  • Genfit outlined a staged US commercialization plan for its NISTM blood-test technology to identify “at-risk” MASH patients at scale.
  • IQVIA projects peak annual US sales above USD 1.5 billion by 2033, implying a long-term royalty stream for Genfit.
  • Adoption is expected to build over coming months via broader reimbursement coverage, guideline inclusion, rising disease awareness from drug launches.
  • Testing volumes are projected to accelerate from 2028 as new MASH therapies expand screening, patient identification, disease monitoring needs.
  • International expansion plans target Europe, Asia via an in vitro diagnostic strategy, subject to required regulatory authorizations.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief on September 09, 2026, and is solely responsible for the information contained therein.